CytomX is a biotechnology company developing the next generation of highly targeted antibody therapeutics. Our vision is to transform lives with safer, more effective therapies.
Our Probody™ Platform represents a disruptive approach to discovering and developing empowered antibodies to treat areas of major unmet medical need, with a primary focus in oncology. The unique selectivity of Probodies expands the therapeutic window for both validated and novel targets, and has the potential to create multiple new classes of safer and more effective therapies. Using our platform, we are enabling the development of new cancer immunotherapy and antibody drug conjugate product candidates. Our novel technology and proprietary Probody Platform has attracted multiple strategic partnerships with industry-leading pharmaceutical companies.
At CytomX, we are led by a seasoned and proven management team and build upon our deep experience and know-how in the fields of antibody drug development, cancer biology and clinical and translational medicine. To accomplish our mission, the CytomX team embraces our corporate values of integrity, commitment, creativity, teamwork, accountability and fun.
CytomX is well-financed by leading life science investors, including Third Rock Ventures, Canaan Partners and the Roche Venture Fund.